Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Study sponsor: Immunic AG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-11-16Actual
Enrollment · participants263Actual
Source updated2024-03-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.